TrialAmerican journal of hematology2013

Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.

Silvia Mangiacavalli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.